Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that CEO Mark Erlander, Ph.D., has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th – 30th from 9:00 AM - 5:00 PM EDT.
|
SAN DIEGO, March 22, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that CEO Mark Erlander, Ph.D., has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th – 30th from 9:00 AM - 5:00 PM EDT.
Details on the presentation can be found below.
In addition to the fireside chat, Dr. Erlander will also provide a pre-recorded overview of Cardiff Oncology's clinical and corporate strategy. The pre-recorded presentation will be available throughout the duration of the conference, which will be streamed live on M-Vest. To attend, sign up to become an M-Vest member here. A replay of the fireside chat will be available by visiting the "Events" section on the investor page of the Cardiff Oncology website after the conference's conclusion. About Cardiff Oncology, Inc. Cardiff Oncology Contact: Investor Contact: Media Contact:
SOURCE Cardiff Oncology, Inc. |
||||||||
Company Codes: NASDAQ-NMS:CRDF |
View original content to download multimedia:
